CHICAGO--(BUSINESS WIRE)--CytoCore, Inc. (OTCBB:CYCR) today announced plans to begin trials for a quick, accurate, inexpensive screening test for endometrial and uterine cancers using a specialized computer-guided image recognition microscope system and the new P2X7 genetic marker to identify pre-cancerous cell changes.
